Masato Nakamura

Professor

Toho University
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Background Combination therapy with atherectomy and intravascular lithotripsy (IVL) has emerged as a promising strategy for the treatment of severely calcified occlusive coronary lesions, which potentially enhances procedural efficacy without increasing complication risk. Methods The Dual-Prep Registry is a multicenter, prospective registry designed to evaluate the safety and efficacy of IVL after atherectomy in severely calcified lesions. Combined use was selectively applied when the risk of complications was anticipated to be high with a larger atherectomy burr size, or when it was deemed non-beneficial due to unfavorable guidewire bias. All adverse events were adjudicated by a clinical events committee. Kaplan-Meier analysis was performed to evaluate the primary endpoint of major adverse cardiovascular events (MACE; composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization [TVR]) at 1 year. Results A total of 118 cases (120 lesions) were enrolled across 20 facilities. Significant comorbidities included diabetes in 56.8% of patients and hemodialysis-dependence in 25.4%. Calcification score after atherectomy was 4.0 in all cases, and calcified nodules were present in 56.4% (core-lab analysis) of cases. One-year follow-up was complete in 99.2% patients. MACE occurred in 7.6% patients at one year (cardiac death 2.5%, myocardial infarction 5.1%, TVR 5.1%) and stent thrombosis was observed in 1 case. Conclusions Atherectomy followed by IVL resulted in low 1-year rates of MACE, TVR, and stent thrombosis in patients with severely calcified coronary lesions. This approach may be considered for lesions where an “IVL-first” strategy is difficult to apply. Japan Registry of Clinical Trials: jRCT1032230384. URL: https://jrct.mhlw.go.jp A Clinical Perspective 1) What Is New? Elective combined use of IVL and atherectomy resulted in low 1 year MACE and TLR. The incidence of MACE was higher in cases with greater residual stenosis after the procedure and a larger baseline reference vessel diameter. 2) What Are the Clinical Implications? Combining IVL with atherectomy may serve as an effective treatment strategy in cases where IVL-first approaches are difficult to apply. Severe calcified lesions that are presumed to be unresponsive to RA/OA treatment or carry a high risk of RA/OA complications may be good candidates for this strategy.

Year:

2025

Background Despite limited clinical evidence, the use of drug-coated balloons (DCB) in percutaneous coronary intervention for de novo coronary lesions is expanding and increasing. Furthermore, recent randomized trial demonstrated that imaging guided DCB improves angiographic outcomes. Methods ALLIANCE is a prospective, multicenter, all-comer registry designed to evaluate the efficacy and safety of the paclitaxel-DCB in an expanded real-world clinical setting. A calculated sample size of 1500 patients was expected to provide 95% power to detect non-inferiority against a performance goal of 7.5% target lesion failure (TLF) at 1 year with a 3.0% absolute non-inferiority margin. Cases in which DCB was performed after successful lesion preparation were consecutively enrolled. The Primary endpoint was TLF, a composite of cardiac death, myocardial infarction and clinically driven target lesion revascularization (cd-TLR) at 1 year. An independent clinical events committee adjudicated all primary endpoint events. Results Between July 2023 and February 2024, 1794 patients (with 1984 lesions) were enrolled at 57 sites in Japan. Mean age was 71 years, 76% of patients were male, 45% had diabetes mellitus, and 29% presented with acute coronary syndromes. Among lesion characteristics, 31% were calcified lesions, 25% showed diffuse disease, 26% were bifurcations, and 38% were treated a greater than 3 mm DCB balloon. Intravascular imaging was used in 88.5% (1755/1984) of lesions. Lesion preparation was performed with modified balloons in 68% of cases and by atherectomy in 19%. Bail-out stenting after DCB was required in 1.1% of patients. The rate of TLF at 1 year was 4.7% overall (95%CI 3.8-5.8%, p non-inferiority <0.001), and cd-TLR 2.9%. Thrombotic events during the follow-up period were limited to one case Conclusions Paclitaxel DCB has proven effective and safe in the current expanding daily clinical practice. Utilizing imaging modalities during DCB procedure may improve DCB treatment outcomes. What is Known? Clinical applications of paclitaxel DCBs are being explored for a variety of lesion subsets and clinical presentations; however, their expanded clinical use has not been validated in large-scale prospective studies. Guidance from imaging devices may enhance the potential of DCBs in routine clinical practice; however, no data demonstrate clinical benefit from the combined use of DCBs and imaging modality. What the study adds? Paclitaxel DCB was effective and safe in various coronary artery lesion and clinical settings in real world practice. The use of an imaging modality may enable optimal preparation of lesions, increasing the inherent potential of DCB in daily practice.

Year:

2025

Background Rhythm control therapy improves the quality of life and prognosis of patients with atrial fibrillation (AF). We assessed the characteristics and clinical outcomes of AF patients with stable coronary artery disease (CAD) undergoing rhythm control therapy. Methods We analyzed 2215 participants from the Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (AFIRE) trial, including 588 patients who received rhythm control therapy and 1627 who did not. Results At baseline, patients who received rhythm control therapy were generally younger, exhibited a higher prevalence of paroxysmal AF, experienced less heart failure, and had lower CHADS2 scores (CHF, hypertension, age ≥ 75 years, type 2 diabetes, and previous stroke or transient ischemic attack [doubled]) than those who did not. Among the rivaroxaban monotherapy and combination therapy groups, patients with a history of rhythm control therapy showed a lower incidence of the primary efficacy endpoint (a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization, or death). However, following multivariate analysis and propensity score matching, no statistically significant difference in the primary efficacy endpoint was observed between patients with and without prior rhythm control therapy (adjusted HR 0.75, 95% CI 0.37–1.51, p = 0.43 in the rivaroxaban group; adjusted HR 0.75, 95% CI 0.43–1.30, p = 0.30 in the combination therapy group). Conclusions The initially observed benefit of rhythm control therapy was not significant after adjusting for baseline characteristics in patients with AF and stable CAD treated with rivaroxaban with or without additional antiplatelet therapy.

Year:

2025

The KCB01 (KIZASHI ™ ) is a novel cutting balloon catheter with blades integrally formed with the balloon. It is designed to overcome the drawbacks of conventional cutting balloons in terms of lesion delivery, crossability and procedural complications while maintaining the same dilation capacity. To evaluate the efficacy and safety of the KCB01, a prospective, open-label, single-arm study was conducted at nine sites in Japan on percutaneous coronary intervention-eligible patients with stenotic lesions that exhibited residual indentation even after conventional balloon dilation at nominal pressure. Seventy-six patients were enrolled between November 2022 and June 2023, and 73 eligible patients were included in the primary analysis. The mean age was 73.5 ± 7.4 years, and 79.5% of the patients were male. The target lesion characteristics included bifurcation lesions (42.5%), in-stent restenosis lesions (20.5%), and severely calcified lesions (54.8%). The primary endpoint was procedural success, defined as the KCB01 crossing the target lesion, no residual indentation, and < 50% residual stenosis rate after KCB01 dilation (assessed using quantitative coronary angiography). The angiographic images obtained during the procedure were evaluated in a core laboratory. The procedural success rate was 87.7% (95% confidence interval [CI]: 77.9–94.2), with the lower limit of the 95% CI (77.9%) exceeding the performance goal of 76.5%. Clinical success rate was achieved in 94.5% of cases (95% CI: 86.6–98.5%), with no major adverse cardiac events reported until discharge. Furthermore, no device deficiencies related to the KCB01 were observed. These results suggest the safety and efficacy of the KCB01. Graphical abstract

Year:

2025

Backgrounds Atrial fibrillation (AF) is a risk factor for adverse cardiovascular outcomes in patients with stable coronary artery disease (CAD). The prognostic relevance of lower systolic blood pressure (SBP) and the optimal antithrombotic strategy in patients with AF and CAD remain to be clarified. Methods This post-hoc analysis of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) trial stratified participants based on median SBP at baseline: >126 mmHg (High SBP group, n=1042) and ≤126 mmHg (Low SBP group, n=1093). The primary efficacy endpoint was a composite of cardiovascular events and all-cause death. The primary safety endpoint was major bleeding. Results The mean SBP was 139 mmHg and 114 mmHg in the High and Low SBP groups, respectively. In the propensity score-matched cohort (n=1684), the Low SBP group had a significantly higher incidence of the primary efficacy endpoint (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.01–1.88; p=0.039), while the primary safety endpoint was comparable between groups. In the Low SBP group, rivaroxaban monotherapy was associated with lower risks of both the primary efficacy (HR, 0.66; 95% CI, 0.41–0.86; p=0.006) and safety endpoints (HR, 0.40; 95% CI, 0.22–0.74; p=0.003) compared with combination therapy, whereas no significant differences were observed in the High SBP group. Conclusions Lower SBP was associated with increased risk of cardiovascular events and all-cause death. Rivaroxaban monotherapy demonstrated more favorable efficacy and safety outcomes compared with combination therapy, particularly among patients with lower SBP.

Year:

2025

Evaluation of calcified lesions by intravascular imaging has revealed that atherectomy devices have only limited impact. However, subsequent use of coronary intravascular lithotripsy (IVL) may increase treatment effectiveness without increasing risk of complications. This study was designed to evaluate the safety and effectiveness of IVL use after atherectomy in severely calcified coronary lesions as pre-treatment for drug-eluting stents (DES). The Dual-Prep registry is a multicenter, prospective registry of consecutive image-guided percutaneous coronary interventions (PCI). The primary effectiveness and safety endpoints were procedural success (residual stenosis < 50% by quantitative coronary angiography) without an in-hospital major adverse cardiac event (MACE) and 30-day freedom from MACE, respectively. Baseline vessel calcification score and final DES expansion were evaluated by optical coherence tomography (OCT). A total of 118 patients with 120 lesions were enrolled at 20 sites. The calcification score of lesions after atherectomy by core-lab assessment was 4.0 in all cases. Rotational atherectomy was applied prior to IVL in 83.9% cases with mean burr size of 1.57 ± 0.20 mm; IVL was subsequently successfully delivered in all cases (mean balloon diameter 3.02 ± 0.45 mm), followed by DES deployment (mean diameter 3.19 ± 0.51 mm, length of 36.3 ± 16.0 mm). The primary efficacy and safety endpoints were met in 98.3% and 98.3% of cases, respectively. A DES expansion index < 0.8 was seen in 42.2%, and an eccentricity index < 0.7 was not observed in any patient. In severely calcified lesions, image-guided atherectomy followed by IVL lesion preparation demonstrated high procedural success rates and satisfactory non-eccentric stent expansion. This approach may be considered for lesions where an ‘IVL-first’ strategy may not be feasible. jRCT1032230384 (Oct 7, 2023). Graphical abstract Dual-Prep registry : atherectomy + IVL before DES implantation strategy for calcified lesion (Calc score ≥ 3 after atherectomy)

Year:

2025

Collaborators (4)

Tetsuya Matoba

Associate Professor

Kyushu University Hospital

JAPAN
View details

Gaku Nakazawa

Kindai University Hospital

JAPAN
View details

Ken Kozuma

-

JAPAN
View details

Junya Ako

Kitasato University

JAPAN
View details